DFDA

Aspirin

Treatment for Lower Extremity Peripheral Arterial Disease

Typical Dosage: 75-325mg daily (typically 81mg or 100mg)

Effectiveness
50%
Safety Score
80%
Clinical Trials
13
Participants
200K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
80
DangerousModerateSafe
Treatment Details
Dosage Range
75-325mg daily (typically 81mg or 100mg)
Time to Effect
Immediate for antiplatelet effect, long-term for CV event reduction
Treatment Duration
Lifetime
Evidence Quality
HIGH
Number Needed to Treat (NNT)
50(Treat 50 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
200(Treat 200 patients to see 1 additional serious adverse event)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$20
Monitoring:$500
Side Effect Mgmt:$50
Total Annual:$570
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENT
ICER
$5,000/QALY
QALYs Gained
0.15
Outcome-Based Costs
Cost per Responder
$108
Aspirin Outcomes

for Lower Extremity Peripheral Arterial Disease

Efficacy Outcomes
Overall Effectiveness
+50%
Response Rate
+65%
Common Side Effects
Gastrointestinal bleeding
+3%
Dyspepsia
+8%
Hemorrhagic stroke (rare)
+0.1%

Sources:

plos.org
researchgate.net
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
3 active trials recruiting for Aspirin in Lower Extremity Peripheral Arterial Disease

Vascular Trial Associated Registry Pilot

NCT07076082RECRUITINGPHASE4
View Study
350 participants
INTERVENTIONAL
Detroit, United States +1 more
Started: Oct 15, 2025

VTE Incidence After Rivaroxaban + Aspirin or SAPT After Lower-limb Revascularization

NCT06873321RECRUITINGPHASE4
View Study
100 participants
INTERVENTIONAL
Pernambuco, Brazil
Started: Feb 24, 2024

Efficacy and Safety of the Regulatory Polypeptides in Patients With Peripheral Atherosclerosis.

NCT05933720RECRUITINGNA
View Study
120 participants
INTERVENTIONAL
Ryazan, Russia
Started: Apr 1, 2023
Completed Clinical Trials
4 completed trials for Aspirin in Lower Extremity Peripheral Arterial Disease

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

NCT02217501COMPLETEDPHASE3
View Study
159 participants
INTERVENTIONAL
Denver, United States +3 more
Started: Nov 1, 2015

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

NCT02504216COMPLETEDPHASE3
View Study
6.56K participants
INTERVENTIONAL
Alexander City, United States +531 more
Started: Aug 18, 2015

Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)

NCT00687076COMPLETEDPHASE4
View Study
102 participants
INTERVENTIONAL
Houston, United States
Started: Apr 1, 2004

Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia

NCT01758874COMPLETEDPHASE2
View Study
20 participants
INTERVENTIONAL
Seoul, South Korea
Started: Sep 1, 2006